Highlander Capital Management’s Edwards Lifesciences EW Stock Holding History

Highlander Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,200	Closed	-$58K	–	737
2018 Q2	$58K	Hold	1,200	–	–	0.03%	334
2018 Q1	$54K	Hold	1,200	–	–	0.03%	341
2017 Q4	$45K	Hold	1,200	–	–	0.03%	367
2017 Q3	$44K	Hold	1,200	–	–	0.03%	373
2017 Q2	$47K	Hold	1,200	–	–	0.04%	359
2017 Q1	$38K	Hold	1,200	–	–	0.03%	393
2016 Q4	$37K	Hold	1,200	–	–	0.03%	399
2016 Q3	$48K	Hold	1,200	–	–	0.04%	357
2016 Q2	$40K	Buy	+1,200	New	+$41.1K	0.04%	396

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Highlander Capital Management's EW Position: Q3 2018 in Review

Highlander Capital Management sold out of Edwards Lifesciences (EW) in Q3 2018, closing a stake of 1,200 shares — an estimated $58K sold.

Highlander Capital Management first reported a position in EW in Q2 2016 and held it in 9 quarters. The position peaked at $58K in Q2 2018. 852 funds tracked by Wall St. Rank hold EW as of Q3 2018.

Highlander Capital Management reported no remaining Edwards Lifesciences position as of Q3 2018 after selling out during the quarter.
Highlander Capital Management sold 1,200 Edwards Lifesciences shares in Q3 2018, an estimated $58K.
Highlander Capital Management first reported a position in Edwards Lifesciences in Q2 2016 and held it in 9 quarters.
Highlander Capital Management's Edwards Lifesciences position peaked at $58K in Q2 2018.
852 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2018.

Based on Highlander Capital Management's 13F filing for Q3 2018, filed 9 Nov 2018.